Matrix Metalloproteinase-2 as Potential Marker of Early Nephropathy in Type 1 Diabetes
American Journal of Internal Medicine
Volume 3, Issue 1, January 2015, Pages: 1-5
Received: Jan. 18, 2015; Accepted: Jan. 29, 2015; Published: Feb. 6, 2015
Views 2669      Downloads 274
Mohamed Fouad, Nephrology unit, Internal Medicine Departments, Zagazig University Hospital, Zagazig, Egypt
Maher Boraie, Clinical Pathology Departments, Zagazig University Hospital, Zagazig, Egypt
Article Tools
Follow on us
Background: Early detection of diabetic nephropathy (DN) is important. Matrix metalloproteinases-2 (MMP-2) regulates a variety of cellular functions including apoptosis and angiogenesis. Diabetic environment stimulates the secretion of MMP-2 that is considered to participate in DN. Objectives: We conducted this study to investigate the level of MMP-2 as a potential marker of early nephropathy in type 1 diabetes. Methods: The total number of the study was 300 participants, among them 100 participants, were healthy volunteers control group with comparable age and sex to other participants (Group 1). The remaining 200 participants were suffering from type 1 diabetes and were categorized according to duration of diabetes into 100 patients had disease duration less than 5 years and all of them non microalbuimnuric (Group 2) and the last 100 patients had disease duration more than 5 years (Group 3). All subjects were submitted to complete clinical examination; routine laboratory investigations, including; random blood sugar (RBS); glycosylated hemoglobin (HbA1C) and quantitative determination of microalbuminuria (MA) for DN. Specific laboratory investigation for MMP-2 by enzyme-linked immunosorbent assay. Results: RBS and HbA-1c were significantly higher in group 3 than group 2. MA significantly detected only in group 3. MMP-2 was significantly higher in group 3 than the other groups 1, 2 and in the meantime significantly higher in group 2 than 1. MMP-2 starts to rise early before the onset of MA in group 2. Eventually duration of diabetes, RBS, HbA1c and MA were positively correlated with the MMP-2 level. (r=0. 44; P<0.05), (r=0. 43; P<0.05), (r=0. 58; P<0.05) and (r=0. 71; P<0.001) respectively. MMP-2 cutoff level of ≥ 311 ng/ml had a greater sensitivity and specificity for identifying MA (P<0.001). Conclusion: MMP-2 level pre-date the clinical evidence of MA, may serve as an important predictor for early development of DN and a potential marker of severity.
Matrix Metalloprteinase-2, Type1 Diabetes Mellitus, Microalbuminuria, Diabetic Nephropathy
To cite this article
Mohamed Fouad, Maher Boraie, Matrix Metalloproteinase-2 as Potential Marker of Early Nephropathy in Type 1 Diabetes, American Journal of Internal Medicine. Vol. 3, No. 1, 2015, pp. 1-5. doi: 10.11648/j.ajim.20150301.11
DCCT: Implications of the Diabetes Control and Complications Trial. American Diabetes Association. Diabetes.1993; 42:1555–1558,
Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA,Lachin J, Genuth S: Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.Diabetes.1999; 48:870–880
Mauch C: Regulation of connective tissue turnover of cell-matrix interactions. Arch Dermatol Res.1998; 290: S30–S36
Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem.1999; 274:21491–21494.
Maisonneuve P, Agodoa L, Gellert Ret al. Distribution of primary renal diseases leading to end-stage renal failure in the United States,Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis.2000; 35: 157–165
Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int.1999; 56: 1627–1637
Furness PN: (1997) Basement membrane synthesis and degradation. J Pathol, 183 (1): 1-3.
Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol.2000; 11: 574–581
McLennan SV, Kelly DJ, Cox AJet al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.Diabetologia. 2002; 45: 268–27
Hernandez-Barrantes S, Shimura Y, Soloway PD, Sang QA, Fridman R: Differential roles of TIMP-4 & TIMP-2inpro-MMP-2 activation by MT1-MMP.Biochem Biophys Res Commun.2001; 281:126–130
Akahane T, Akahane M, Shah A, Thorgeirsson UP. TIMP-1stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun.2004; 1: 440-5.
Han X, Sun Y, Scott S, Bleich D. Tissue inhibitor of metalloproteinase-1 prevents cytokine -mediated dysfunction and cytotoxicity in pancreatic islets and beta-cells. Diabetes.2001; 50: 1047-55
American Diabetes Association: Diabetic nephropathy (Position Statement). Diabetes Care.2000; 23 (Suppl. 1): S69–S72
Bahman P, Tabaei M , AL-K assab , Liza L,I lag ,Cathernen M, Zawacki RN and William H. Herman. Does Microalbuminuria Predict Diabetic Nephropathy?. Diabetes Care.2001; 24:1560 –1566
Zelmanovitz T, Gerchmann F, Balthazar A, Thomazelli F, Matos J, and Canani L, : Diabetic nephropathy: Diabetology and metabolic syndrome. 2009; 1:10.
Sedegheh Gharagozlian, Katja Svennevig, Hans-Jacob Bangstad , JanOlof Winberg and Svein Olav Kolset..MMP in subjects with type 1diabetes BMC; Clinical Pathology.2009; 9:7 doi: 10. 1186 /1472 -6890-9-7
Mai M Y, Hoda A, Sawsan T, Hanaa S, Ola M, Manal A M, Nagham M, B, A., MMP-2 as a marker of microvascular complications in Children and Adolescents with Type 1 Diabetes Mellitus. Macedonian Journal of Medical Sciences.2011; 15; 4 (1): 81-88. doi:10.3889/MJMS.1857-5773.2011.0151.
Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL: MMP-2 Dysregulation in Type I Diabetes. Diabetes Care.2007; 30 (9): 2321-2326
Flory B, Glowinska B, urban M, Peczynska J. MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes, Edokrynol Diabetol Chor Przemiany Materii Wieku Rozw.2006; 12 (3): 184-189.
Ming-Yuh Shiau, Shih-Tzer Tsai, Kan-Jen Tsai, Ming-Lih Haung, Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. THE MOUNT SINAI JOURNAL OF MEDICINE.2006; Vol. 73 No. 7.
Symeonidis C(1), Papakonstantinou E, Galli A, Tsinopoulos I, Mataftsi A, Batzios S, Dimitrakos SA.. Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes. Graefes Arch Clin Exp Ophthalmol.2013; 251 (3): 741-9.
Kanwar K, Wada J, Lin Sun, Ping Xie, Elisabith I, Sumnat C, and Nad Farhad R: Diabetic nephropathy: Mechanisms of renal disease progression: Exp Biol Med.2007; 233:4-11.
Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF: Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia.2007; 37 (5): 483-490.
Zelmanovitz T, Gerchmann F, Balthazar A, Thomazelli F, Matos J, and Canani L, : Diabetic nephropathy: Diabetology and metabolic syndrome. 2009; 1:10.
Sophia Zoungas, Sophia Zoungas, Mark Woodward, Qiang Li, Mark E. Cooper, Pavel Hamet et al. (2014). Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia.2014;DOI: 10. 1007 /s00125-014 -3369 -7
Jacek Rysz, Maciej Banach, Robert A. Stolarek, Jaroslaw Pasnik, et al (2007). MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in DN.JNEPHROL.2007;; 20: 444-452
Messent JWC, Elliott TG&Hill RD, et al. (1992) Prognostic significance of microalbuminuria in Insulin- dependent diabetes mellitus: A twenty-three year follow-up study. Kidney Int; 41: 836−839
Derosa G, Avanzini MA, Geroldi D, Fogari R, Lorini R, De Silvestri A,et al: (2005) Matrix MMP- 2may be a marker of microangiopathy in children and adolescents with type I diabetes Diabetes Res Clin Pract.; 70 (2): 119-125
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186